#1292ef

Ajanta Pharma Limited

#f9f9f9

Mannalal Agrawal

Madhusudan Agrawal

Yogeah Agrawal

Rajesh Agrawal

Arvind Agrawal

Jainandra Kumar Tripathi

Rajeev Agrawal

Harsh Soni

Prasad Menon

Sandeep Amlekar

Prashant Lohar

Kartvyasinh Vaghela

Nilesh A. Sawant

Nilotpal Choudhury

Yatin Parab

Satyajit Sahoo

Suresh Pandey

Surinder Pal Singh

Sandeep K

Nitin Ambre

Kuldeep Tyagi

Ganesh Masne

Venkatakrishnan L

Jayesh Chaudhary

Sudip Nagar

Amiya Kumar Padhy

Arun Kumar Singh

Ramkumar Subramanian

Shailendra Sharma

Nandkishore Agrawal

Arun Seth

Mani Kuriakose

Surjya Panda

Jitendra Ranade

Satish Agrawal

Shirish Deshpande

Prafull Bhandari

Piku Saini

Manohar Lalge

Abhay Mahajan

Sonal Sangodkar

Shailesh Kulkarni

Raja Dileep Gupta

Arun Malik

Sandeep Gadewar

Deepak Nikam

Minesh Desai

Jayakumar A V

Yogesh Joshi

Shriram Pohnerkar

Dinesh Khairnar

Anamika Singh

Vivek Kapur

Vandana Kasbekar

Rohit Gacche

Dinesh Shukla

Divya Amin

Bhalchandra Javdekar

Vishal Patel

Parag Shetye

Anant Sawant

Milind Satwik

Harish Upadhyay

Somnath Rahane

Robin Antony

Nitin Patil

Vikas Choudhary

Mahalaxmi Andheria

Prabhakar Sonawane

Santosh Singh

Dipak Pawar

Atul Harshe

Vinayak Deshpande

Ravindranath Deshpande

Pankaj Joshi

Shashikant Ghare

Prasad Shahane

Vijay Dabade

Shrinivas Saraf

Vikas N B.

Mohan Shelke

Biplab Mishra

Amarkumar Singh

Dinabandhu Ray

Sumit Das

Parashar Deka

Ravindra Mankar

Dharmesh Dangodara

Sambhaji Kolhe

Sanjeev Goyal

Sunil Dixit

Sanjay Dharia

Satish Iprul

Ajay Donga

#87c5f2

Finance

Sales & Marketing

Cardiac Division

DERMATOLOGY

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India.  It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.

In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management.  Its brands in each of sub-therapeutic areas or molecules hold leadership positions.

In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc. 

As on 31 March 2020, Ajanta has 30 ANDA approvals which are commercialised. And we are awaiting US FDA approval for 22 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.

We have state-of-the-art research facilities for formulation and API development located at Mumbai, India.  Our R&D capabilities are evident from number of products launched 1st to market by the company providing patients most needed compliance and convenience. A dedicated and focused team of over 650+ Ajantaites work for R&D, which is growing continuously. 

Ajanta has Six formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, we also have an API manufacturing facility located at Waluj, India.  Ajanta’s flagship formulation facility at Paithan (Maharashtra, India) and Dahej (Gujarat, India) has been approved by stringent authorities like USFDA.    We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet the company’s growth requirements.

We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet company’s growth requirements.

Please visit http://ajantapharma.com/ for more information.